Markets
Supreme Court Rules Affirmative Action Is Unconstitutional In Landmark Case With Harvard And UNC
Harvard Yard at Harvard University (Scott Eisen/Getty Images)
Weird Money

The fund managers for Ivy League endowments somehow managed to flop in this market

The reduced volatility of private equity comes with a cost.

Jack Raines

Over the weekend, the Financial Times published an interesting piece on Ivy League endowment returns so far this year. Per the FT, through the 12-month period ending June 2024, six of the eight Ivies underperformed the higher-education average. And, in 2023, all of the Ivies returned below the higher-education average of 6.8%. For context, the S&P 500 was up 24% in 2023.

One reason for the Ivy woes? An overallocation to private equity. From the Financial Times: 

Top endowments have long used aggressive exposure to private investments in pursuit of excess returns they believe are out of reach through public markets. Now, as those investments have yet to pay off, some large endowments like Princeton have issued bonds to meet funding needs, according to the New Jersey Educational Facilities Authority…

Most Ivy League endowments had earmarked more than 30%, and in the case of Yale and Princeton at least 40%, of their assets to PE and VC by the first half of the year, according to Old Well Labs, a financial data provider.

One reason that Ivy League schools have increasingly turned to private equity is that it offers lower volatility than public markets. Minimizing volatility is important for these endowments because they are responsible for funding a portion of their schools’ operating budgets each year. For example, in fiscal year 2024, Harvard’s endowment distributed $2.4 billion to cover 37% of the school’s operating budget. While the Ivies have underperformed over the last couple of years, that reduced volatility paid off in one year. In 2022, the S&P 500 was down 18.1%, but Harvard’s endowment only fell by 1.8%, and Yale’s endowment actually increased by 0.8%. When you have to make multibillion-dollar distributions each year, minimizing risk is far more important than maximizing returns, and private equity offers lower volatility.

However, the reduced volatility of private equity comes at a cost: illiquidity. There was an interesting phenomenon in 2022, where public markets sold off sharply but private-market valuations were less affected. While some private companies may have been more resilient, firms also sold far less of their portfolio companies in 2022 than the year before: exit volume was down 57% year over year through Q3 2022.

If a bucket of publicly traded fintech SaaS companies fell by 50%, you would think that, by correlation, the value of similar-sized privately held fintech SaaS companies would decline by 50%, too. But if the PE firms that own these similarly-sized fintech SaaS companies can say, “Our valuations have only declined by 15%,” and continue to hold those portfolio companies, then boom, outperformance. Of course, there probably aren’t any willing buyers at this valuation (hence the 57% decline in exit volume), but, at least on their own books, private-equity portfolios looked resilient.

However, because endowments have to distribute cash to help fund their universities’ budgets, valuations and “returns” don’t mean much if they don’t eventually yield exits that return cash, and distributions have been slow over the last three years. The result: Ivy League schools have had to issue nearly $3 billion in municipal debt so far through October 2024, up 650% from the year before, to help meet these cash needs.

Paper returns look good, but at the end of the day, an investment is only worth what someone else will pay for it. If you say your company is worth $1 billion, but no one else is willing to pay more than $700 million to acquire it, is it really worth $1 billion? Probably not, as endowments have figured out.

More Markets

See all Markets
markets

Health insurance stocks lose steam as Trump says he’ll lobby insurers for lower prices

Shares of health insurance companies dropped Friday afternoon, as President Trump said he would ask insurers to meet with him in the coming weeks to seek lower prices.

Stocks including Humana, UnitedHealthcare, Cigna, CVS Health, and Elevance Health all either pared gains or went further into the red after Trump’s remarks, which came at the end of a press event to announce pricing deals with nine drugmakers.

“I’m going to call a meeting of the big insurance companies that have gotten so rich,” Trump said, noting that he would lobby them for lower prices.

“I would say that maybe with one talk, they would be willing to cut their prices by 50, 60, or 70%. They’ve made a fortune.”

markets

Rivian’s surge continues as stock reaches highest level since December 2023 on analyst upgrades

Shares of EV maker Rivian are on pace to close up double digits for the second day in a row on Friday as bullish investors pour into the stock following analyst upgrades.

Rivian shares were up more than 10% on Friday afternoon, with the stock climbing to its highest level since December 2023.

Webush’s Dan Ives boosted his Rivian price target by 56% to $25 in a note on Friday morning. The analyst wrote that 2026 is a “prove-me” year for the automaker, with its lower-cost R2 model set to launch in the first half.

Ives’s note follows a separate optimistic bit of analysis from Baird, which also boosted its Rivian price target to $25 in a note on Thursday.

If today's gains hold, Friday will mark the third day of double-digit gains for Rivian in the past six trading days. An “AI Day” event that saw the automaker detail autonomous updates and tease a robotaxi plan started the recent run.

markets

The neoclouds are shooting back up into the stratosphere

Investors’ faith in tech CEOs’ pursuit of digital God has seemingly been restored for now, sparking an intense rally in the speculative AI players that had been in full-on meltdown mode over concerns that the boom had passed its best-before date.

The data center companies colloquially known as the “neoclouds” — CoreWeave, Nebius, IREN, and Cipher Mining — are up more than double digits over the past two sessions, as of 10:40 a.m. ET.

The past 48 hours have brought a steady drumbeat of positive news for the AI theme.

CoreWeave received a vote of confidence from Wall Street as Citi resumed coverage with a buy rating and price target of $135. Oracle, the epicenter of AI credit concerns, has seen a reversal in its fortunes as it nears an acquisition of TikTok’s US operations. And OpenAI’s fundraising efforts appear be going so well that its reported valuation has gone up in back-to-back days.

Before that, Micron’s earnings reaffirmed the intense demand for AI compute, which continues to outstrip supply — a positive sign for the neoclouds. The macro backdrop is also turning perhaps a bit more in favor of lower interest rates, as CPI inflation came in well below expectations.

Snoop Dogg Performs At OVO Hydro Glasgow

Marijuana rescheduling could mean more investment in US weed stocks. There aren’t many ways in.

“Yes, institutional capital will go into the underlying names. The question is: How fast?" one weed company chairman said.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.